Phase III Double-Blind, Placebo Controlled, Prospective Randomized Comparison of Adjuvant Therapy with Tamoxifen vs. Tamoxifen and Fenretinide in Postmenopausal Women with Positive Receptors, Intergroup

Phase III double-blind, placebo-controlled, prospective randomized trial of adjuvant tamoxifen vs. tamoxifen and fenretinide in postmenopausal women with positive receptors (EB193): an intergroup trial coordinated by the Eastern Cooperative Oncology Group [PMID20878269]

RD Rao;M Cobleigh;R Gray;ML Graham;L Norton;S Martino;GT Budd;JN Ingle;WC Wood Medical Oncology 28 Suppl 1:S39-47;

Fenretinide (FEN) vs placebo in postmenopausal breast cancer patients receiving adjuvant tamoxifen (TAM), an Eastern Cooperative Oncology Group Phase III Intergroup Trial (EB193, INT-0151)

MA Cobleigh;R Gray;M Graham;L Norton;S Martino;GT Budd;JN Ingle;NE Davidson;WC Wood Proc of the American Society of Clinical Oncology 19:86a(#328)